Are the claims of a research start-up that is seeking to crowd-fund HIV vaccine research credible?
17 February 2014 | Wired
The Immunity Project is an initiative to crowd-source money to make a new HIV vaccine. However many scientists are sceptical: "It seems like they’re going straight to the public and making appeals to emotion because they don’t have the scientific background to establish themselves in the research community," says virologist Abbie Smith at Emory University in Atlanta, Georgia.
11 February 2014 | Nature
Some people contract HIV and never get sick. These people are called “controllers,” and studying them has long been a focus for researchers seeking a cure for the disease. Now, an ambitious plan called The Immunity Project has released a white paper outlining how they plan to create an HIV vaccine—free for the entire world population—based on the computerized analysis of blood from HIV controllers.
10 February 2014 | Healthline
Anthony Fauci argues that while broader global access to antiretroviral therapies and wider implementation of proven HIV prevention strategies could potentially control and perhaps end the HIV/AIDS pandemic, a safe and at least moderately effective HIV vaccine is needed to reach this goal more expeditiously and in a more sustainable way.
06 February 2014 | Eurekalert Inf Dis
Researchers at Duke University have mapped the structure of a key part of the HIV envelope protein, the gp41 membrane proximal external region (MPER), the spot where some of the most effective antibodies found in HIV patients bind and disable the virus. The discovery will aid vaccine research.
14 January 2014 | Duke University press release
Dong-Pyou Han, PhD, an assistant professor of biomedical sciences at Iowa State University, has resigned after admitting he tampered with HIV vaccine research, the Des Moines Register reports
30 December 2013 | Poz magazine news
Researchers have launched an early-stage clinical trial of an investigational vaccine designed to prevent genital herpes disease. The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is sponsoring the Phase I trial, which is being conducted at the NIH Clinical Center in Bethesda, Md.
09 November 2013 | Eurekalert Inf Dis
Studies of a potential vaccine target bolster claims that an earlier paper was flawed.
05 November 2013 | Nature
Increased attention to the delivery of HIV prevention and treatment programmes is needed to prepare communities for a potential roll-out of a vaccine, which will most probably be partially-effective, experts say.
24 October 2013 | IRIN
If a breakthrough in developing an HIV vaccine occurred today, scientists and drug companies would need another decade to provide a commercial product. But, after a long struggle, researchers may indeed have made that breakthrough using a new vaccine approach that combines two prior ones. Given that the AIDS pandemic has been around for 30 years and has claimed 36 million lives, with 35 million more people currently infected with the HIV virus, the long-awaited goal might finally be attainable, according to researchers attending the 13th Aids Vaccine Conference last week in Barcelona.
18 October 2013 | Scientific American